文献速递临床试验与 GCP基础与转化研究流行病学与生物统计

ELSA试验:非禁用β2受体激动剂单用与联用对骨骼肌代谢、心肺功能及耐力运动表现的影响——一项随机四周期平衡交叉试验的研究方案

The ELSA trial: single versus combinatory effects of non-prohibited beta-2 agonists on skeletal muscle metabolism, cardio-pulmonary function and endurance performance-study protocol for a randomized 4-way balanced cross-over trial.
PubMed 文献 · Trials · 2021-12-11

ELSA试验为双盲、安慰剂对照、随机、四周期平衡交叉研究,纳入24名参与者(12女、12男),随机顺序完成四个研究阶段:安慰剂、沙丁胺醇、福莫特罗、福莫特罗+沙丁胺醇。参与者在10分钟计时赛前20分钟吸入研究药物,计时赛中以最高可能功率骑行10分钟,持续监测心输出量,计时赛后3小时采集骨骼肌活检。研究终点包括骨骼肌核受体表达、激素与细胞因子水平、尿和血浆中沙丁胺醇与福莫特罗浓度、循环心脏标志物、心肺功能及运动表现(计时赛平均功率和峰值功率);计时赛后24小时采集血尿并做呼吸测试。该试验评估非禁用、无医学指征的吸入短效和长效β2受体激动剂对骨骼肌基因表达、内分泌调节、心脏生物标志物、心肺功能及急性耐力运动表现的潜在增强作用,数据将供世界反兴奋剂机构(WADA)用于调整每年发布的禁用物质清单(WADA 2021),并将在科学期刊发表。

要点

  • ELSA试验为双盲、安慰剂对照、随机、四周期平衡交叉研究,纳入24名参与者(12女、12男)。
  • 四个研究阶段为安慰剂、沙丁胺醇、福莫特罗、福莫特罗+沙丁胺醇,按随机顺序完成。
  • 参与者在10分钟计时赛前20分钟吸入研究药物,计时赛中以最高可能功率骑行10分钟。

核心结论

  • 该临床试验评估非禁用、无医学指征的吸入短效和长效β2受体激动剂对骨骼肌基因表达、内分泌调节、心脏生物标志物、心肺功能及急性耐力运动表现的潜在增强作用。
  • 研究数据将供世界反兴奋剂机构(WADA)用于调整每年发布的禁用物质清单(WADA 2021),并将在科学期刊发表。

研究设计与样本

  • ELSA试验为双盲、安慰剂对照、随机、平衡、四周期交叉研究。
  • 研究参与者共24名(12女、12男),在初始初步测试后按随机顺序完成四个研究阶段(治疗A安慰剂、B沙丁胺醇、C福莫特罗、D福莫特罗+沙丁胺醇)。
  • 参与者在10分钟计时赛(TT;运动表现测试)前20分钟吸入研究药物,计时赛中以最高可能功率骑行10分钟,持续测量心输出量,计时赛后3小时采集骨骼肌活检。
  • 研究终点包括骨骼肌核受体表达、激素和细胞因子水平、尿和血浆中沙丁胺醇与福莫特罗浓度、循环心脏标志物、心肺功能及运动表现(计时赛平均功率和峰值功率)。
  • 计时赛后24小时采集血和尿并进行呼吸测试。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Asthma and/or airway hyper-responsiveness (AHR) are common in elite endurance athletes with a high prevalence rate of beta-2 adrenoreceptor (beta-2) agonists use. Nevertheless, there are data on dose-dependent ergogenic effects of beta-2 agonists suggesting increased muscle strength, endurance and neuromuscular performance. Therefore, most beta-2 agonists belong to the World Anti Doping Agency (WADA) list of prohibited substances and it is tempting to speculate that illegitimate use of beta-2 agonists might be a common practice to boost performance in competitive sports. It is currently unknown whether or not inhaled beta-2 agonists enhance performance by stimulatory effects in skeletal and cardiac muscle. METHODS: The ELSA trial is a double-blinded, placebo-controlled, randomized, balanced, four-way cross-over study. Study participants (n=24, 12 ♀, 12 ♂) complete four study arms (i.e. periods with treatment A, placebo; B, salbutamol; C, formoterol; D, formoterol + salbutamol) in random order after an initial preliminary testing session. Participants inhale the study medication 20 min before the 10-min time trial (TT; exercise performance test), where participants cycle 10 min at the highest possible workload. Cardiac output is measured continuously. A skeletal muscle biopsy is collected 3 h after the TT. Study endpoints include measures of skeletal muscle expression of nuclear receptors, hormones and cytokine levels, urinary and plasma concentrations of salbutamol and formoterol, circulating cardiac markers, cardiopulmonary function and exercise performance (average power and peak power during the TT). Blood and urine are collected and respiratory testing is performed 24 h post TT. This clinical trial evaluates the potential performance-enhancing effects of non-prohibited, not medically indicated inhaled short- and long-acting beta-2 agonists on skeletal muscle gene expression, endocrine regulation, cardiac biomarkers, cardiopulmonary function and acute endurance exercise performance. These data will be used by WADA to adapt the annually published list of prohibited substances (WADA 2021) and will be published in scientific journals. TRIAL REGISTRATION: The trial is registered at the European Clinical Trials Database (Eudra CT) with the number: 2015-005598-19 as well as at the German register for clinical studies (DRKS number 00010574 ).

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Zügel M, Bizjak DA, Nussbaumer D, et al. The ELSA trial: single versus combinatory effects of non-prohibited beta-2 agonists on skeletal muscle metabolism, cardio-pulmonary function and endurance performance-study protocol for a randomized 4-way balanced cross-over trial. Trials. 2021. PMID: 34895300. doi:10.1186/s13063-021-05862-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。